| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Michael Iskedjian, Thomas R Einarso. Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease. PharmacoEconomics. vol 21. issue 2. 2003-03-10. PMID:12515573. |
ropinirole, a dopamine agonist, is associated with fewer dyskinesias than levodopa. |
2003-03-10 |
2023-08-12 |
Not clear |
| Frédéric Calon, Thérèse Di Paol. Levodopa response motor complications--GABA receptors and preproenkephalin expression in human brain. Parkinsonism & related disorders. vol 8. issue 6. 2003-03-05. PMID:12217634. |
these data are consistent with previous observations in mptp monkeys developing dyskinesias following ld or dopamine agonist treatment. |
2003-03-05 |
2023-08-12 |
human |
| Aimee Di Marco, Linda S Appiah-Kubi, K Ray Chaudhur. Use of the dopamine agonist cabergoline in the treatment of movement disorders. Expert opinion on pharmacotherapy. vol 3. issue 10. 2003-03-03. PMID:12387694. |
cabergoline has been shown to be as effective as other dopamine agonists in improving motor function as monotherapy in early pd, and a 5-year levodopa-controlled study indicates the superiority of cabergoline over levodopa in reducing dyskinesias. |
2003-03-03 |
2023-08-12 |
Not clear |
| Eleni C Maratos, Michael J Jackson, Ronald K B Pearce, Carla Cannizzaro, Peter Jenne. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus). Experimental neurology. vol 179. issue 1. 2003-01-30. PMID:12504871. |
both short- and long-acting d-1/d-2 dopamine agonists induce less dyskinesia than l-dopa in the mptp-lesioned common marmoset (callithrix jacchus). |
2003-01-30 |
2023-08-12 |
marmoset |
| Eleni C Maratos, Michael J Jackson, Ronald K B Pearce, Carla Cannizzaro, Peter Jenne. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus). Experimental neurology. vol 179. issue 1. 2003-01-30. PMID:12504871. |
the current concept of dyskinesia is that pulsatile stimulation of d-1 or d-2 receptors by l-dopa or short-acting dopamine agonists is more likely to induce dyskinesia compared to long-acting drugs producing more continuous receptor stimulation. |
2003-01-30 |
2023-08-12 |
marmoset |
| Eleni C Maratos, Michael J Jackson, Ronald K B Pearce, Carla Cannizzaro, Peter Jenne. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus). Experimental neurology. vol 179. issue 1. 2003-01-30. PMID:12504871. |
these data suggest that factors other than duration of drug action may be important in the induction of dyskinesia but support the use of dopamine agonists in early parkinson's disease, as a means of delaying l-dopa therapy and reducing the risk of developing dyskinesia. |
2003-01-30 |
2023-08-12 |
marmoset |
| Regina Katzenschlager, Andrew J Lee. Treatment of Parkinson's disease: levodopa as the first choice. Journal of neurology. vol 249 Suppl 2. 2003-01-17. PMID:12375059. |
studies in animal models and in humans show that these motor complications are not specific to a particular dopaminergic agent, but that they are related both to the extent of the striatal lesion and to the mode of application of dopaminergic agents: pulsatile administration of l-dopa and of the dopamine agonist apomorphine causes more motor complications than continuous striatal dopaminergic receptor stimulation, and continuous administration can alleviate existing dyskinesias and fluctuations. |
2003-01-17 |
2023-08-12 |
Not clear |
| Regina Katzenschlager, Andrew J Lee. Treatment of Parkinson's disease: levodopa as the first choice. Journal of neurology. vol 249 Suppl 2. 2003-01-17. PMID:12375059. |
three medium-term (3-5 years) and one 10-year study showed less dyskinesia in the first five years of treatment in patients who had started therapy with a dopamine agonist. |
2003-01-17 |
2023-08-12 |
Not clear |
| Yilong Ma, Andrew Feigin, Vijay Dhawan, Masafumi Fukuda, Qiuhu Shi, Paul Greene, Robert Breeze, Stanley Fahn, Curt Freed, David Eidelber. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Annals of neurology. vol 52. issue 5. 2002-12-03. PMID:12402261. |
persistent dyskinesias in the absence of or with only minimal amounts of dopaminergic medication have been reported after dopamine cell implantation for parkinson's disease. |
2002-12-03 |
2023-08-12 |
Not clear |
| Erwin B Montgomer. Two advances in the management of Parkinson disease. Cleveland Clinic journal of medicine. vol 69. issue 8. 2002-10-10. PMID:12184472. |
levodopa should generally be avoided early in the course of parkinson disease; dopamine agonists, particularly second-generation agents such as ropinirole (requip) and pramipexole (mirapex), carry a smaller long-term risk of dyskinesia and should be used instead. |
2002-10-10 |
2023-08-12 |
Not clear |
| M C Porter, L S Appiah-Kubf, K R Chaudhur. Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist. International journal of clinical practice. vol 56. issue 6. 2002-09-27. PMID:12166546. |
cabergoline has also been used as monotherapy in pd and has been shown to be as effective as other dopamine agonists in improving motor function and to be superior to levodopa in reducing dyskinesias over a five-year period. |
2002-09-27 |
2023-08-12 |
Not clear |
| W J Hwang, D B Calne, J K Tsui, R de la Fuente-Fernánde. The long-term response to levodopa in dopa-responsive dystonia. Parkinsonism & related disorders. vol 8. issue 1. 2002-06-20. PMID:11472874. |
we propose that the dopamine turnover might decrease with time, which would lead to a decrease in the requirement for levodopa and the occurrence of dyskinesias late in the course of drd. |
2002-06-20 |
2023-08-12 |
Not clear |
| Taizo Nakazato, Akitane Akiyam. Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease. Brain research. vol 930. issue 1-2. 2002-06-07. PMID:11879803. |
evidence suggests that l-dopa induces increases in dopamine, which then binds to supersensitive dopamine receptors, resulting in dyskinesia. |
2002-06-07 |
2023-08-12 |
rat |
| P W Overstall, C E Clark. Uncertainties in the pharmacotherapy of Parkinson's disease and how to solve them. Gerontology. vol 48. issue 1. 2002-04-09. PMID:11844927. |
long-term trials with the old and newer dopamine agonists as monotherapy have shown that as a class they can delay the development of dyskinesia and probably response fluctuations. |
2002-04-09 |
2023-08-12 |
Not clear |
| Kazuya Kannari, Kozo Kurahashi, Masahiko Tomiyama, Tetsuya Maeda, Akira Arai, Masayuki Baba, Toshihiro Suda, Muneo Matsunag. [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease]. No to shinkei = Brain and nerve. vol 54. issue 2. 2002-04-02. PMID:11889759. |
a rapid and excessive increase in extracellular dopamine(da) after l-dopa administration is considered one of the major causes for l-dopa-induced peak-dose dyskinesia. |
2002-04-02 |
2023-08-12 |
rat |
| M A Silverdale, A R Crossman, J M Brotchi. Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia. Experimental neurology. vol 174. issue 1. 2002-03-28. PMID:11869030. |
long-term levodopa or dopamine agonist treatment in the mptp-lesioned primate model of parkinson's disease elicits dyskinesia, which is phenotypically similar to levodopa-induced dyskinesia in patients with parkinson's disease. |
2002-03-28 |
2023-08-12 |
monkey |
| O Rascol, N Fabr. Dyskinesia: L-dopa-induced and tardive dyskinesia. Clinical neuropharmacology. vol 24. issue 6. 2002-02-20. PMID:11801806. |
in both cases, unprimed patients not previously exposed to the offending drugs, are offered alternative medications to reduce, at least partly, the risk of occurrence of future dyskinesia: "atypical" neuroleptics in the place of "typical" neuroleptics, and dopamine agonists in the place of l-dopa. |
2002-02-20 |
2023-08-12 |
human |
| O Rascol, N Fabr. Dyskinesia: L-dopa-induced and tardive dyskinesia. Clinical neuropharmacology. vol 24. issue 6. 2002-02-20. PMID:11801806. |
based on limited clinical evidence, it is a common proposal to switch the dyskinetic subject from "typical" to "atypical" neuroleptics for tardive dyskinesia, or to switch from (or more pragmatically to substitute as much as possible) l-dopa to a dopamine agonist for l-dopa-induced dyskinesia. |
2002-02-20 |
2023-08-12 |
human |
| O Rascol, N Fabr. Dyskinesia: L-dopa-induced and tardive dyskinesia. Clinical neuropharmacology. vol 24. issue 6. 2002-02-20. PMID:11801806. |
there are some uncontrolled data suggesting that dopamine depleting agents, like tetrabenazine, are possibly useful for tardive dyskinesia; however, there is more clinical evidence to support the efficacy of amantadine and functional surgery in parkinsonian patients with l-dopa-induced dyskinesia. |
2002-02-20 |
2023-08-12 |
human |
| E C Maratos, M J Jackson, R K Pearce, P Jenne. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus). Movement disorders : official journal of the Movement Disorder Society. vol 16. issue 4. 2001-10-18. PMID:11481686. |
de novo administration of long-acting dopamine agonists, such as ropinirole, to patients with parkinson's disease or to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (mptp)-treated subhuman primates produces a lower incidence of dyskinesia than occurs with l-dopa. |
2001-10-18 |
2023-08-12 |
marmoset |